Skip to content

Author

He-Cheng Li

We have 9 of 42 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Sep 2026

Perioperative treatment for resectable non-small cell lung cancer harboring EGFR exon 20 insertion mutations: a narrative review from advanced-stage evidence to whole-course precision management

Advanced-stage evidence supports perioperative investigation but cannot establish benefit in resectable disease, and progress requires accurate variant-level testing and randomized trials defining pathological response, surgical feasibility, toxicity, central nervous system (CNS) control, DFS, and OS.

Zhuo-Ran Li, Yi-Chao Han, Wen-Zhao Zhong et al. · 0 citations
Review Open access Sep 2026

The Adjuvant-Phase Dilemma After Neoadjuvant Chemoimmunotherapy in Resectable NSCLC: Evidence and Response-Guided Strategies

Simple Summary Perioperative immunotherapy, which includes treatment before and after surgery, has improved outcomes for some patients with resectable non-small cell lung cancer. However, current clinical trials usually test the entire treatment plan rather than the separate value of continuing immunotherapy after surg...

Jing-Yuan Fan, Yi-Chao Han, Run-Sen Jin et al. · 0 citations
Open access Aug 2026

PD09.07. Impact of Type 2 Diabetes on Outcomes of Neoadjuvant Therapy and Surgery for Esophageal Cancer: A Multi-Center Retrospective Study

Type 2 diabetes was not associated with increased perioperative morbidity or impaired long-term survival following neoadjuvant therapy and surgery following esophageal cancer patients receiving neoadjuvant therapy and surgery.

Xi-Peng Wang, Zhi-Chao Liu, Xue-Feng Leng et al. · 0 citations
Review Sep 2026

Recent Advances and Future Challenges of Bispecific Antibodies in Lung Cancer.

Bispecific antibodies (BsAbs) integrate two binding specificities to coordinate antitumor mechanisms that cannot be readily achieved with conventional monospecific antibodies. In lung cancer, these agents encompass four principal strategies: dual targeting of tumor-associated receptors, immune-cell redirection, simulta...

Ming-Yuan Du, Yi-Chao Han, Run-Sen Jin et al. · 0 citations
Aug 2026

P1.086. Impact of Surgery Versus Non-Surgery on the Prognosis of Esophageal Cancer Patients With Clinically Identified Metastatic Supraclavicular Lymph Nodes

Surgical resection may offer a survival benefit for patients with esophageal cancer and SCLN metastases, supporting its role in specific cases, and tumor location should be recognized as a determinant in therapeutic decision.

Yi-Heng Huang, Yu-Qin Cao, He-Cheng Li · 0 citations
Open access Jul 2026

Targeting the FOXP3—T-bet interaction to restore Treg stability in IFN-γ—driven autoimmunity 2254306

Regulatory T cells (Tregs) maintain immune homeostasis through FOXP3-centered transcriptional complexes that tightly control lineage stability and suppressive function. However, how specific FOXP3 mutations disturb this complex and drive pathogenic Treg reprogramming in IPEX syndrome remains unclear. We identifie...

Bin Li, Wei-Qi Zhang, Xin-Nan Liu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.